High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma
Cancer Immunology, Immunotherapy · 2024
DOI: 10.1007/s00262-024-03799-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2024. Verfasst von Samuel L Hill und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. s.l.hill@soton.ac.uk. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Programmed Cell Death 1 Receptor, Adenocarcinoma, Lymphocytes, Tumor-Infiltrating. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Royal College of Surgeons of England.
Abstract (Originalsprache)
Objective
To understand the CD8+ tumour infiltrating lymphocyte (TIL) compartment of oesophageal adenocarcinoma (OAC) with regards to markers of lymphocyte exhaustion, tissue residency and to identify possible reasons behind differential responses to therapy.
Design
Tumour samples from 44 patients undergoing curative resection for OAC were assessed by flow cytometry for presence of antigen-experienced TILs and markers of activation and exhaustion. Populations of PD-1 and CD39 positive OAC TILs were sorted, and bulk RNA sequencing undertaken using a modified SmartSeq2 protocol. Flow cytometric assessment of functionality was completed.
Results
A higher proportion of antigen experienced CD8+ OAC TILs was associated with improved survival following surgery; while, high double positivity (DP) for PD-1 and CD39 among these TILs also correlated significantly with outcome. These DP TILs possess a minority population which is positive for the markers of exhaustion TIM3 and LAG3. Transcriptomic assessment of the PD-1 and CD39 DP TILs demonstrated enrichment for a tissue resident memory T lymphocyte (TRM) phenotype associated with improved survival in other cancers, reinforced by positivity for the canonical TRM marker CD103 by flow cytometry. This population demonstrated maintained functional capacity both in their transcriptomic profile, and on flow cytometric assessment, as well as preserved proliferative capacity.
Conclusion
Resected OAC are variably infiltrated by PD-1 and CD39 DP TILs, an abundance of which among lymphocytes is associated with improved survival. This DP population has an increased, but still modest, frequency of TIM3 and LAG3 positivity compared to DN, and is in keeping with a functionally competent TRM phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. s.l.hill@soton.ac.uk.
- School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
- Oxford Cancer Centre for Immuno-Oncology and CAMS-Oxford Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Förderung
- Cancer Research UK
- Royal College of Surgeons of England
Zitieren
APA
Hill, S. L., Sugiyarto, G., Harrington, J., James, E., Underwood, T. J., & Elliott, T. (2024). High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-024-03799-y
Vancouver
Hill SL, Sugiyarto G, Harrington J, James E, Underwood TJ, Elliott T. High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma. Cancer Immunology, Immunotherapy. 2024. doi:10.1007/s00262-024-03799-y
BibTeX
@article{Hill2024,
author = {Hill, Samuel L and Sugiyarto, Gessa and Harrington, Jack and James, Edward and Underwood, Timothy J and Elliott, Tim},
title = {High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma},
journal = {Cancer Immunology, Immunotherapy},
year = {2024},
doi = {10.1007/s00262-024-03799-y}
}
EUVIMED